Cargando…
Engineered immunological niches to monitor disease activity and treatment efficacy in relapsing multiple sclerosis
Relapses in multiple sclerosis can result in irreversible nervous system tissue injury. If these events could be detected early, targeted immunotherapy could potentially slow disease progression. We describe the use of engineered biomaterial-based immunological niches amenable to biopsy to provide i...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398910/ https://www.ncbi.nlm.nih.gov/pubmed/32747712 http://dx.doi.org/10.1038/s41467-020-17629-z |
_version_ | 1783566039956586496 |
---|---|
author | Morris, Aaron H. Hughes, Kevin R. Oakes, Robert S. Cai, Michelle M. Miller, Stephen D. Irani, David N. Shea, Lonnie D. |
author_facet | Morris, Aaron H. Hughes, Kevin R. Oakes, Robert S. Cai, Michelle M. Miller, Stephen D. Irani, David N. Shea, Lonnie D. |
author_sort | Morris, Aaron H. |
collection | PubMed |
description | Relapses in multiple sclerosis can result in irreversible nervous system tissue injury. If these events could be detected early, targeted immunotherapy could potentially slow disease progression. We describe the use of engineered biomaterial-based immunological niches amenable to biopsy to provide insights into the phenotype of innate immune cells that control disease activity in a mouse model of multiple sclerosis. Differential gene expression in cells from these niches allow monitoring of disease dynamics and gauging the effectiveness of treatment. A proactive treatment regimen, given in response to signal within the niche but before symptoms appeared, substantially reduced disease. This technology offers a new approach to monitor organ-specific autoimmunity, and represents a platform to analyze immune dysfunction within otherwise inaccessible target tissues. |
format | Online Article Text |
id | pubmed-7398910 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-73989102020-08-13 Engineered immunological niches to monitor disease activity and treatment efficacy in relapsing multiple sclerosis Morris, Aaron H. Hughes, Kevin R. Oakes, Robert S. Cai, Michelle M. Miller, Stephen D. Irani, David N. Shea, Lonnie D. Nat Commun Article Relapses in multiple sclerosis can result in irreversible nervous system tissue injury. If these events could be detected early, targeted immunotherapy could potentially slow disease progression. We describe the use of engineered biomaterial-based immunological niches amenable to biopsy to provide insights into the phenotype of innate immune cells that control disease activity in a mouse model of multiple sclerosis. Differential gene expression in cells from these niches allow monitoring of disease dynamics and gauging the effectiveness of treatment. A proactive treatment regimen, given in response to signal within the niche but before symptoms appeared, substantially reduced disease. This technology offers a new approach to monitor organ-specific autoimmunity, and represents a platform to analyze immune dysfunction within otherwise inaccessible target tissues. Nature Publishing Group UK 2020-08-03 /pmc/articles/PMC7398910/ /pubmed/32747712 http://dx.doi.org/10.1038/s41467-020-17629-z Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Morris, Aaron H. Hughes, Kevin R. Oakes, Robert S. Cai, Michelle M. Miller, Stephen D. Irani, David N. Shea, Lonnie D. Engineered immunological niches to monitor disease activity and treatment efficacy in relapsing multiple sclerosis |
title | Engineered immunological niches to monitor disease activity and treatment efficacy in relapsing multiple sclerosis |
title_full | Engineered immunological niches to monitor disease activity and treatment efficacy in relapsing multiple sclerosis |
title_fullStr | Engineered immunological niches to monitor disease activity and treatment efficacy in relapsing multiple sclerosis |
title_full_unstemmed | Engineered immunological niches to monitor disease activity and treatment efficacy in relapsing multiple sclerosis |
title_short | Engineered immunological niches to monitor disease activity and treatment efficacy in relapsing multiple sclerosis |
title_sort | engineered immunological niches to monitor disease activity and treatment efficacy in relapsing multiple sclerosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7398910/ https://www.ncbi.nlm.nih.gov/pubmed/32747712 http://dx.doi.org/10.1038/s41467-020-17629-z |
work_keys_str_mv | AT morrisaaronh engineeredimmunologicalnichestomonitordiseaseactivityandtreatmentefficacyinrelapsingmultiplesclerosis AT hugheskevinr engineeredimmunologicalnichestomonitordiseaseactivityandtreatmentefficacyinrelapsingmultiplesclerosis AT oakesroberts engineeredimmunologicalnichestomonitordiseaseactivityandtreatmentefficacyinrelapsingmultiplesclerosis AT caimichellem engineeredimmunologicalnichestomonitordiseaseactivityandtreatmentefficacyinrelapsingmultiplesclerosis AT millerstephend engineeredimmunologicalnichestomonitordiseaseactivityandtreatmentefficacyinrelapsingmultiplesclerosis AT iranidavidn engineeredimmunologicalnichestomonitordiseaseactivityandtreatmentefficacyinrelapsingmultiplesclerosis AT shealonnied engineeredimmunologicalnichestomonitordiseaseactivityandtreatmentefficacyinrelapsingmultiplesclerosis |